Full Breakdown
DRC’s Bundibugyo Ebola Outbreak: Scale, Response, and Ongoing Challenges
By Drooid · · How we work
Outbreak Overview
The Democratic Republic of the Congo (DRC) is confronting its 17th Ebola epidemic, declared on May 15. The outbreak is caused by the rare Bundibugyo strain, for which no approved vaccine or specific treatment exists. The epicenter lies in Ituri province, with spread to six additional provinces. Health-ministerial data released on October 1 2026 report 4,018 deaths among 8,300 confirmed cases. More than 2,000 patients have recovered, and the case-fatality rate is estimated at 48.4 %.
Background & Context
The Bundibugyo virus emerged rapidly after the May declaration, outpacing contact-tracing in a region already destabilised by armed conflict and displacement. International partners—including WHO, Africa CDC, and MSF—have warned that the epidemic is “far from over.”
Data & Statistics
- Confirmed cases: 8,300 (seven provinces)
- Deaths: 4,018 (government data, October 2 2026)
- Fatality rate: 48.4 %
- Health-zone trends: 12 zones have reported no new cases for 42 days (Health Minister Roger Kamba).
Clinical Trial for Post-Exposure Prophylaxis
A trial of Gilead’s experimental antiviral pill obeldesivir began in July at a health centre in Ituri. More than 250 participants—including health workers and relatives of patients—have enrolled. Coordinated by ALIMA, the study targets nearly 1,000 adults and children (>=12 years) exposed within five days but asymptomatic. Participants receive either the drug or a placebo and are monitored daily for 21 days, with a follow-up call at day 42.
Official Statements & Responses
- WHO emphasizes expanding capacity in intense-transmission zones and rapid intervention in emerging hotspots.
- MSF described the situation as “like fighting a wildfire.”
On-the-Ground Reports
Trial participants report heightened anxiety after household exposures. A enrollee who joined in August after her husband tested positive said she avoided further contact and has not seen any family members develop symptoms. Health workers note that a mobile laboratory team in Butembo reduced test turnaround from 72 hours to six hours, improving rapid case identification.
Conflicting Reports & Gaps
- Death toll: Government figures list 4,018 deaths (Reuters, October 2), while MSF refers to “more than 4,000” and an earlier briefing cited 3,901 deaths.
- Surveillance: UN officials note that only about one-fifth of identified contacts in the burned Kigonze transit centre have been traced.
Verbatim Quotes
- “When we lose a centre, that means we lose capacity, we lose investment and we have to start again.” — Julien Harneis
- “It is like fighting a wildfire,” — Stephanie Hoffman
- “We are no longer talking about outbreaks at the provincial level, but outbreaks concentrated in individual health zones,” — Health Minister Roger Kamba
What’s Next
The obeldesivir trial will continue enrolling toward its 1,000-person target, with results expected later in the year. Health-ministerial briefings indicate several zones have achieved 42 days without new cases, suggesting localized containment. Authorities plan to maintain mobile labs, expand safe-burial teams, and increase bed capacity to over 1,800 across 54 facilities, pending additional staffing. Continued security improvements and community engagement remain essential to prevent further spread.